<p>Factors associated with receipt of Erlotinib among patients diagnosed in 2010 with stage IV non-small cell lung cancer, Patterns of Care.</p
The authors surveyed the pattern of care (POC) of lung cancer (LC) using data on 4565 patients from ...
Rationale, aims and objectives Molecular targeted drugs (MTD), gefitinib and erlotinib, have been pr...
Erlotinib is used to treat non-small-cell lung cancer (NSCLC). Erlotinib was subsidized on the Pharm...
<p>Frequency of <i>EGFR</i> testing and receipt of erlotinib among non-small cell lung cancer patien...
<p>Association between <i>EGFR</i>-mutant status and Erlotinib treatment with all-cause survival amo...
This study determined the frequency and factors associated with EGFR testing rates and erlotinib tre...
Purpose Erlotinib is an orally administered tyrosine kinase inhibitor used for treatment of non-smal...
<div><p>Despite being the basis of one of the most effective interventions in lung cancer, little is...
Copyright © 2014 Josephine Krainhöfer et al. This is an open access article distributed under the C...
Background: The efficacy of erlotinib is controversial in patients with unknown EGFR mutational stat...
<p>Clinicopathological characteristics of NSCLC patients at diagnosis classified as responders and n...
IntroductionBR.21 demonstrated significant survival benefit for non-small cell lung cancer patients ...
Aims and background:Erlotinib approval was supported by the positive results of a large multicentric...
This study determined the frequency and factors associated with EGFR testing rates and erlotinib tre...
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors increase survival and improve qua...
The authors surveyed the pattern of care (POC) of lung cancer (LC) using data on 4565 patients from ...
Rationale, aims and objectives Molecular targeted drugs (MTD), gefitinib and erlotinib, have been pr...
Erlotinib is used to treat non-small-cell lung cancer (NSCLC). Erlotinib was subsidized on the Pharm...
<p>Frequency of <i>EGFR</i> testing and receipt of erlotinib among non-small cell lung cancer patien...
<p>Association between <i>EGFR</i>-mutant status and Erlotinib treatment with all-cause survival amo...
This study determined the frequency and factors associated with EGFR testing rates and erlotinib tre...
Purpose Erlotinib is an orally administered tyrosine kinase inhibitor used for treatment of non-smal...
<div><p>Despite being the basis of one of the most effective interventions in lung cancer, little is...
Copyright © 2014 Josephine Krainhöfer et al. This is an open access article distributed under the C...
Background: The efficacy of erlotinib is controversial in patients with unknown EGFR mutational stat...
<p>Clinicopathological characteristics of NSCLC patients at diagnosis classified as responders and n...
IntroductionBR.21 demonstrated significant survival benefit for non-small cell lung cancer patients ...
Aims and background:Erlotinib approval was supported by the positive results of a large multicentric...
This study determined the frequency and factors associated with EGFR testing rates and erlotinib tre...
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors increase survival and improve qua...
The authors surveyed the pattern of care (POC) of lung cancer (LC) using data on 4565 patients from ...
Rationale, aims and objectives Molecular targeted drugs (MTD), gefitinib and erlotinib, have been pr...
Erlotinib is used to treat non-small-cell lung cancer (NSCLC). Erlotinib was subsidized on the Pharm...
DOI
Add to ORKG